INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma

NCT03692338 · clinicaltrials.gov ↗
NA
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class

Stopped Poor accrual

Conditions

Interventions

Sponsor

Duke University

Collaborators